2 Israeli cos report success in blood sugar monitoring

OrSense and Glucon have both developed products for non-invasive blood sugar measurement.

Two Israeli companies, OrSense and Glucon have presented good results of clinical tests at the American Diabetes Association’s 66th Scientific Sessions, in Washington, D.C. This is considered to be one of the most important conferences in the field and Israel is considered a minor powerhouse for development of new diabetes monitoring technologies. OrSense and Glucon were the only companies to present clinical results in non-invasive blood sugar testing, one of the hot issues on the conference agenda and one of the big technological challenges in the field today.

OrSense has developed a device for blood sugar testing that uses a strong optical signal, yielding a high signal-to-noise ratio that is blood driven. A study of 24 patients at the Sheba Hospital at Tel Hashomer found that the readings obtained using the OrSense device were as accurate as those obtained using regular invasive testing of type I and type II diabetes patients, under home conditions.

In his presentation to the Washington conference, director of the endocrinology institute at Sheba Hospital Professor Avraham Karasik, said, “We believe that OrSense’s glucose monitoring system is set to become the system for real-time blood sugar monitoring of diabetes patients under home conditions.”

Glucon has also developed a device for blood-sugar measurement, which works by reading blood glucose levels directly from a blood vessel, without puncturing the skin, through the use of a novel photo-acoustic (optical and sound-based) technology. Glucon’s device was also shown by a clinical study to be as precise as invasive blood sugar measurement devices. Its device was tested in a study of 62 patients and was presented at the conference by Dr. Ram Weiss, a senior pediatric endocrinologist at Hadassah - Hebrew University School of Medicine in Jerusalem.

Both companies have yet to conduct clinical trials according to US Food and Drug Administration (FDA) protocols, and to prove that their devices are precise enough to be approved as alternatives to the invasive glucometer devices (which give readings by finger pricking), currently used by diabetes patients.

Glucon said it believed its product would be on the market by as early as 2007. OrSense is also set to begin clinical trials of its product this year.

Published by Globes [online], Israel business news - www.globes.co.il - on June 13, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018